Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Gastrointestinal 1CNS 1

Conditions

Neoplasms 1Leukemia, Myeloid, Acute 1Glioma 1Cholangiocarcinoma 1

Interventions

pembrolizumab 18Bevacizumab 14Carboplatin 11Standard of Care 9Nivolumab 9Pemetrexed 7Exercise 7Cyclophosphamide 7Cetuximab 7atezolizumab 6Temozolomide 6Cisplatin 6durvalumab 5Prednisone 5Paclitaxel 5Fluorouracil 5Doxorubicin 5130-nm albumin-bound paclitaxel 5abemaciclib 4Leucovorin 4Gemcitabine 4Docetaxel 4Dexamethasone 4Blood Specimen Collection 4venetoclax 3temsirolimus 3olaparib 3ibrutinib 3enzalutamide 3dostarlimab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Cytochrome P-450 CYP2C9 × 30 days × Clear all
NCT07486713 2026-06-05

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Rigel Pharmaceuticals

Phase 4 Recruiting
16 enrolled
CNSGastrointestinalOther hematologic neoplasm

Glioma, Neoplasms, Leukemia, Myeloid, Acute, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡